Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Financial Information for the Company's Reportable Segments

The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands):

	Three Months Ended June 30, 2025
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	8,543	$	1,190	$	—	$	9,733
Other revenue	250		69		—		319
Provision for credit losses	761		—		—		761
Interest expense	240		4		911		1,155
Pharmaceutical manufacturing, research and development expense	—		645		—		645
Depreciation and amortization expense	—		—		19		19
General and administrative expense	72		592		2,179		2,843
Other expense, net	(67)		—		—		(67)
Income tax expense	—		—		1,026		1,026
Net income (loss)	7,653		18		(4,135)		3,536

	Three Months Ended June 30, 2024
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	9,986	$	804	$	—	$	10,790
Other revenue	57		—		—		57
Provision for credit losses	4,095		—		—		4,095
Loss on impairment of intangible assets	—		5,771		—		5,771
Interest expense	225		2		892		1,119
Pharmaceutical manufacturing, research and development expense	—		520		—		520
Change in fair value of acquisition-related contingent consideration	—		(4,900)		—		(4,900)
Depreciation and amortization expense	—		400		21		421
General and administrative expense	91		747		2,082		2,920
Other income (expense), net	3,851		—		(37)		3,814
Income tax expense	—		—		1,035		1,035
Net income (loss)	9,483		(1,736)		(4,067)		3,680

	Six Months Ended June 30, 2025
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	19,255	$	2,153	$	—	$	21,408
Other revenue	360		116		—		476
Benefit from credit losses	(704)		—		—		(704)
Interest expense	472		6		1,807		2,285
Pharmaceutical manufacturing, research and development	—		1,403		—		1,403
Depreciation and amortization expense	—		—		38		38
General and administrative expense	127		1,296		4,697		6,120
Other expense, net	(2,281)		(82)		—		(2,363)
Income tax expense	—		—		2,304		2,304
Net income (loss)	17,439		(518)		(8,846)		8,075

	Six Months Ended June 30, 2024
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	21,021	$	1,083	$	—	$	22,104
Other revenue	103		—		—		103
Provision for credit losses	9,392		—		—		9,392
Loss on impairment of intangible assets	—		5,771		—		5,771
Interest expense	590		5		1,780		2,375
Pharmaceutical manufacturing, research and development expense	—		1,050		—		1,050
Depreciation and amortization expense	—		892		43		935
Change in fair value of acquisition-related contingent consideration	—		(4,900)		—		(4,900)
General and administrative expense	169		1,457		3,978		5,604
Other income (expense), net	3,843		—		(411)		3,432
Income tax expense	—		—		1,264		1,264
Net income (loss)	14,816		(3,192)		(7,476)		4,148

Schedule of Total Assets for the Company's Reportable Segments

The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):

	June 30, 2025		December 31, 2024
Total Assets
Finance receivables	$	253,459	$	299,248
Pharmaceutical development and other	8,976		7,786
Holdings Company and other	23,262		25,201
Total	$	285,697	$	332,235